概括
神经息治疗支持患有严重神经疾病的儿童及其家属,重点关注长期健康挑战中的生活质量. 它强调了共同的决策和全面的支持,而不仅仅是医疗干预.
科学领域:
- 儿科神经学 儿科神经学
- 抚慰性护理是一种缓解性护理.
- 儿童神经学 儿童神经学
背景情况:
- 儿童神经病学的进步使得对复杂疾病的精确诊断和家庭护理成为可能.
- 家庭面临着长期的不确定性,大量的决策,以及重大的护理负担.
- 神经系统疾病可能会阻碍患者的直接沟通,需要专注于孩子的最佳利益和经验.
研究的目的:
- 对患有严重疾病的儿童进行神经治疗护理的独特方面进行描述.
- 突出共享决策,医疗管理和护理中的系统级因素.
- 举例说明医疗保健如何受到健康脆弱性和长期残疾的影响.
主要方法:
- 这篇文章综合了神经息护理当前的知识和临床实践.
- 它回顾了儿童神经病学中共享决策的原则.
- 它检查了影响医疗保健提供服务的医疗保健系统因素.
主要成果:
- 神经息治疗解决了严重神经疾病儿童的长期需求.
- 有效的护理包括协作决策和对儿童和家庭的整体支持.
- 系统层面的因素显著影响神经息护理的提供和有效性.
结论:
- 神经息疗法对于支持患有严重神经疾病的儿童及其家属至关重要.
- 它超越了生命终点护理,专注于在几年或几十年内提高生活质量.
- 儿童神经科医生能够在所有级别的实践中实施神经治疗护理策略.
更多相关视频
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
3.4K
07:39Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
3.9K
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
195
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
195
Pharmacokinetics in Pediatric Patients: Drug Metabolism
176
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
Pharmacokinetics in Pediatric Patients: Drug Distribution
244
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
244
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
231
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
231
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Continuing Care
1.8K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.8K
